Tag: drug eluting balloon catheter market share analysis

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Drug Eluting Balloons Catheters Market Size, Value And Growth Trajectory Through 2030

The drug eluting balloons catheters market size has seen rapid growth in recent years. This market is expected to increase from $1.65 billion in 2025 to $1.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. The expansion witnessed during the historic period is due to factors such as the rising incidence of coronary artery disease, the increasing adoption of percutaneous coronary interventions, advancements in balloon catheter materials, the clinical acceptance of paclitaxel-coated devices, and the proliferation of interventional cardiology centers.

The drug eluting balloons catheters market size is anticipated to undergo substantial growth in the forthcoming years. It is projected to expand to $2.92 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This expansion throughout the forecast period stems from the escalating demand for minimally invasive vascular therapies, the increasing embrace of sirolimus-based balloons, the broadening array of peripheral vascular disease treatments, rising investments in next-generation catheter technologies, and a greater emphasis on long-term patient outcomes. Significant developments foreseen in this period encompass the growing adoption of drug-coated balloon technologies, their increased utilization in coronary and peripheral interventions, an evolving preference for stent-free treatment options, the advancement of sophisticated drug coating techniques, and a sharpened focus on preventing restenosis.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=82733096&type=smp&name=Drug%20Eluting%20Balloons%20Catheters%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Eluting Balloons Catheters Market Growth Backed By Core Demand Fundamentals

The increasing occurrence of peripheral and cardiovascular ailments is projected to drive expansion in the drug-eluting balloon catheter market in the future. Cardiovascular diseases (CVDs) encompass various conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) is characterized by constricted arteries limiting blood flow mainly to the limbs. Drug-eluting balloon catheters offer a therapeutic approach for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon covered with an anti-proliferative agent, designed to exert an anti-restenotic impact upon insertion into a blood vessel. A notable example is data from January 2024, where the American Heart Association, a US-based non-profit organization, reported that the age-adjusted cardiovascular disease mortality rate climbed to 233.3 deaths per 100,000 in 2024, representing a 4.0% year-on-year increase from 224.4 deaths per 100,000 in 2023. Consequently, the rising incidence of peripheral and cardiovascular conditions is fueling the drug-eluting balloon catheter market.

Drug Eluting Balloons Catheters Market Segment Landscape And Growth Outlook

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters

3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

Drug Eluting Balloons Catheters Market Growth Trends Reshaping The Competitive Landscape

Key players within the drug-eluting balloon catheter market are intensifying their efforts to create cutting-edge, next-generation products incorporating sophisticated technologies, aiming to secure a competitive advantage. For example, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering and medical device manufacturing multinational, declared that its AGENT Drug-Coated Balloon (DCB) had received approval from the U.S. Food and Drug Administration (FDA). The AGENT DCB represents the first drug-coated coronary balloon available in the U.S. designed to address in-stent restenosis (ISR), a condition characterized by plaque or scar tissue obstructing a vessel that has been stented. This device incorporates a paclitaxel coating which delivers a therapeutic dosage directly to the vessel wall, thereby lowering the chances of ISR recurring without requiring further stents or radiation therapy. Clinical studies demonstrated a 49% decrease in heart attack risk at the treated location and indicated minimal occurrences of adverse events.

Drug Eluting Balloons Catheters Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

View The Full Drug Eluting Balloons Catheters Market Report:

https://thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Eluting Balloons Catheters Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Drug Eluting Balloons Catheters Market In 2026 And 2030?

The drug eluting balloons catheters market size has recently shown rapid expansion. It is projected to increase from $1.65 billion in 2025 to $1.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. The historical growth of this market can be attributed to several factors, including the rising prevalence of coronary artery disease, the increasing adoption of percutaneous coronary interventions, ongoing advancements in balloon catheter materials, the clinical acceptance of paclitaxel-coated devices, and the expansion of interventional cardiology centers.

The drug eluting balloons catheters market is projected to experience rapid growth over the next few years, with its size expected to reach $2.92 billion in 2030, growing at a compound annual growth rate (CAGR) of 11.9%. This expansion during the forecast period can be attributed to factors such as the escalating demand for minimally invasive vascular therapies, the increasing adoption of sirolimus-based balloons, the broadening availability of peripheral vascular disease treatments, a rise in investments dedicated to next-generation catheter technologies, and a heightened focus on ensuring long-term patient outcomes. Significant trends expected in this period include the expanding uptake of drug-coated balloon technologies, their increased utilization in coronary and peripheral interventions, a rising inclination towards stent-free treatment options, the proliferation of advanced drug coating techniques, and an intensified concentration on preventing restenosis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which Factors Are Influencing The Growth Of The Drug Eluting Balloons Catheters Market?

The expansion of the drug-eluting balloon catheter market is anticipated to be fueled by the increasing occurrence of peripheral and cardiovascular diseases. Cardiovascular diseases (CVDs) encompass various conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) specifically involves narrowed arteries restricting blood flow, predominantly to the limbs. Drug-eluting balloon catheters serve as a treatment for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon covered with an anti-proliferative agent, which, upon entering the blood vessel, can prevent restenosis. For example, data from January 2024 by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted cardiovascular disease mortality rate escalated to 233.3 deaths per 100,000 in 2024, marking a 4.0% year-on-year increase from 224.4 deaths per 100,000 in 2023. Consequently, the increasing incidence of peripheral and cardiovascular diseases is a key factor propelling the drug-eluting balloon catheter market.

Which Segment Categories Are Included In The Drug Eluting Balloons Catheters Market Segment Analysis?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters

3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

Which Trends Are Influencing Demand In The Drug Eluting Balloons Catheters Market?

Leading companies operating within the drug-eluting balloon catheter market are intensifying their focus on developing the latest generation of products featuring advanced technologies to gain a competitive edge. For instance, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, announced its receipt of U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). This AGENT DCB is recognized as the first drug-coated coronary balloon available in the U.S. for treating in-stent restenosis (ISR), a condition where plaque or scar tissue obstructs a stented vessel. The device utilizes a paclitaxel coating to deliver a therapeutic dose to the vessel wall, effectively reducing ISR recurrence without the need for additional stents or radiation. Clinical trials indicated a 49% decrease in heart attack risk at the target site and reported low rates of adverse events.

Who Are The Active Companies Shaping The Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Get The Full Drug Eluting Balloons Catheters Market Report:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Region Represents The Largest Share Of The Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Eluting Balloons Catheters Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2026, By The Business Research Company

Drug Coated Balloons Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report

Pta Balloon Catheter Market Report 2026

https://www.thebusinessresearchcompany.com/report/pta-balloon-catheter-global-market-report

Deflectable Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/deflectable-catheters-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Drug Eluting Balloons Catheters Market During 2026–2030?

The drug eluting balloons catheters market size has demonstrated rapid expansion in recent years. Its valuation is anticipated to increase from $1.65 billion in 2025 to $1.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.5%. The expansion observed historically can be linked to the rising prevalence of coronary artery disease, the increasing acceptance of percutaneous coronary interventions, enhancements in balloon catheter materials, the clinical endorsement of paclitaxel-coated devices, and the wider establishment of interventional cardiology centers.

The drug eluting balloons catheters market is anticipated to experience substantial growth over the coming years. This market is projected to reach a valuation of $2.92 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. The expansion throughout the forecast period is propelled by factors such as the increasing demand for minimally invasive vascular therapies, the rising adoption of sirolimus-based balloons, the broadening of peripheral vascular disease treatments, growing investments in next-generation catheter technologies, and a heightened focus on long-term patient outcomes. Significant trends expected during this period involve the increasing embrace of drug-coated balloon technologies, their growing utilization in coronary and peripheral interventions, a developing preference for stent-free treatment options, the advancement of sophisticated drug coating techniques, and an intensified focus on preventing restenosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which Major Factors Are Driving The Expansion Of The Drug Eluting Balloons Catheters Market?

The expansion of the drug-eluting balloon catheter market is anticipated due to the increasing incidence of peripheral and cardiovascular diseases. Cardiovascular diseases (CVDs) encompass conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) involves constricted arteries leading to diminished blood flow, mainly in the limbs. Drug-eluting balloon catheters serve as a treatment for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon covered with an anti-proliferative agent that delivers an anti-restenotic impact upon entering a blood vessel. As an illustration, data from January 2024, provided by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted mortality rate for cardiovascular disease climbed to 233.3 deaths per 100,000 in 2024, marking a 4.0% year-on-year increase from 224.4 deaths per 100,000 in 2023. Consequently, the increasing occurrence of both peripheral and cardiovascular diseases is a key driver for the drug-eluting balloon catheter market.

How Are The Various Segments Of The Drug Eluting Balloons Catheters Market Categorized?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters

3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

What Trends Are Affecting The Expansion Of The Drug Eluting Balloons Catheters Market?

Leading companies operating within the drug-eluting balloon catheter market are intensifying their focus on creating next-generation products equipped with advanced technologies to gain a competitive edge. For instance, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, announced it had secured U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). AGENT DCB is the inaugural drug-coated coronary balloon available in the U.S. for treating in-stent restenosis (ISR), a condition where plaque or scar tissue blocks a stented vessel. It incorporates a paclitaxel coating that delivers a therapeutic dose to the vessel wall, thereby reducing ISR recurrence without needing additional stents or radiation. Clinical trials demonstrated a 49% reduction in heart attack risk at the target site and reported low rates of adverse events.

Which Major Firms Influence Developments In The Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Read the full drug eluting balloons catheters market report here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Region Currently Holds The Largest Share Of The Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Drug Eluting Balloons Catheters Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2026, By The Business Research Company

Drug Coated Balloons Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report

Pta Balloon Catheter Market Report 2026

https://www.thebusinessresearchcompany.com/report/pta-balloon-catheter-global-market-report

Deflectable Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/deflectable-catheters-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Drug Eluting Balloons Catheters Market?

The drug eluting balloons catheters market has experienced substantial expansion in recent years. Projections indicate that this market will expand from $1.65 billion in 2025 to $1.86 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. This historical growth can be linked to several factors, including the rising incidence of coronary artery disease, increased uptake of percutaneous coronary interventions, improvements in balloon catheter materials, widespread clinical acceptance of paclitaxel-coated devices, and the proliferation of interventional cardiology centers.

The drug eluting balloons catheters market size is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a valuation of $2.92 billion, expanding at a compound annual growth rate (CAGR) of 11.9%. Factors contributing to this growth during the forecast period include a rising demand for minimally invasive vascular treatments, greater acceptance of sirolimus-based balloons, the broadening scope of peripheral vascular disease therapies, increased funding for advanced catheter technologies, and a heightened emphasis on durable patient results. Key developments expected in the forecast period encompass the wider embrace of drug-coated balloon technologies, an uptick in their application for coronary and peripheral procedures, a growing inclination towards treatment alternatives that do not involve stents, the proliferation of sophisticated drug coating methods, and a sharpened focus on preventing restenosis.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which Drivers Are Supporting The Rise Of The Drug Eluting Balloons Catheters Market?

The increasing incidence of peripheral and cardiovascular diseases is anticipated to drive the expansion of the drug-eluting balloon catheter market in the future. Cardiovascular diseases (CVDs) encompass various ailments affecting the heart and circulatory system, while peripheral artery disease (PAD) is characterized by constricted arteries limiting blood supply, mainly to the limbs. Drug-eluting balloon catheters serve as a treatment method for coronary artery disease (CAD), utilizing a semi-compliant angioplasty balloon infused with an anti-proliferative agent, which produces an anti-restenotic impact upon deployment within a vessel. As an illustration, the American Heart Association, a US-based non-profit organization, reported in January 2024 that the age-adjusted cardiovascular disease mortality rate increased to 233.3 deaths per 100,000 in 2024, representing a 4.0% year-on-year rise from 224.4 deaths per 100,000 in 2023. Consequently, the expanding occurrence of peripheral and cardiovascular diseases is fueling the drug-eluting balloon catheter market.

What Leading Segments Are Studied In The Drug Eluting Balloons Catheters Market?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease, Peripheral Vascular Disease, Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Coronary Drug-Eluting Balloon Catheters, Coronary In-Stent Restenosis Drug-Eluting Balloon Catheters, Coronary Small-Vessel Drug-Eluting Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Femoro-Popliteal Drug-Eluting Balloon Catheters, Below-the-Knee (BTK) Drug-Eluting Balloon Catheters

3) By Drug-Eluting Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

Which Market Trends Are Opening Growth Opportunities In The Drug Eluting Balloons Catheters Market?

Major companies in the drug-eluting balloon catheter market are increasingly focused on developing advanced, newest-generation products to secure a competitive advantage. For instance, in March 2024, Boston Scientific Corporation, a US-based biomedical/biotechnology engineering firm and multinational medical device manufacturer, announced it received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). The AGENT DCB is the first drug-coated coronary balloon available in the U.S. for treating in-stent restenosis (ISR), a condition where plaque or scar tissue blocks a stented vessel. It features a paclitaxel coating that delivers a therapeutic dose to the vessel wall, effectively reducing ISR recurrence without requiring additional stents or radiation. Clinical trials revealed a 49% decrease in heart attack risk at the target site and reported low rates of adverse events.

Which Major Firms Are Strengthening Their Position In The Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Regions Are Poised For Strategic Growth In The Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drug Eluting Balloons Catheters Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2026, By The Business Research Company

Drug Coated Balloons Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-coated-balloons-global-market-report

Pta Balloon Catheter Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pta-balloon-catheter-global-market-report

Deflectable Catheters Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/deflectable-catheters-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Drug Eluting Balloons Catheters Market Expected To Become By 2029 Compared With Its 2025 Level?

The sphere of drug-eluting balloon catheters has experienced swift expansion lately; projections indicate a rise from $1.43 billion in 2024 to $1.65 billion in 2025, reflecting a compounded annual growth rate totaling 15.4%. This historical upward trend is propelled by several factors, including the prevalence of respiratory ailments, the benefits these catheters offer compared to older inhaler methods, increased patient acceptance of dpis, supportive governmental programs focused on respiratory wellness, strategic alliances forged between entities, enhancements in how drugs are prepared, and the aging demographic’s growth.

Forecasting indicates that the drug-eluting balloon catheters sector is poised for substantial expansion in the approaching years, projected to reach a valuation of $2.62 billion by 2029, reflecting a compound annual growth rate of 12.2%. This upward trajectory throughout the forecasted timeframe stems from several key factors such as the persistent rise in respiratory ailments, the expanding segment of the elderly population, heightened levels of awareness and patient education, penetration into nascent global markets, development of personalized drug compositions, supportive regulatory frameworks, and advancements in the physical packaging and structural configuration of the devices. Significant shifts observed during this period are characterized by the integration of smart inhaler technology with connectivity features, a movement favoring inhalers activated purely by the patient’s breath, increased attention directed towards the specific requirements of pediatric and elderly users, the incorporation of biologics for therapeutic delivery, and a growing emphasis on creating inhalation device models that are more ecologically sustainable.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which Drivers Are Supporting Growth Of The Drug Eluting Balloons Catheters Market?

The increasing incidence of both peripheral and cardiovascular ailments is anticipated to fuel the expansion of the market for drug-eluting balloon catheters in the future; these cardiovascular conditions affect the heart and vascular network, while peripheral artery disease specifically involves constricted arteries diminishing blood circulation, predominantly in the limbs, and drug-eluting balloon catheters serve as an intervention for coronary artery disease, utilizing a semi-compliant angioplasty balloon impregnated with an anti-proliferative agent designed to exert an anti-restenotic influence upon deployment within the vessel, as exemplified by data shared in May 2024 from the US government agency, the Centers for Disease Control and Prevention, indicating that heart disease was responsible for 702,880 fatalities in 2022, representing one fifth of all deaths, and furthermore, roughly 805,000 individuals in the United States suffer a heart attack annually, with 605,000 being initial occurrences and 200,000 happening to those with a prior history, consequently highlighting that the escalating rate of these vascular and cardiac diseases is the impetus behind the market growth for drug-eluting balloon catheters.

What Are The Segment Types Shaping The Drug Eluting Balloons Catheters Market?

The drug eluting balloons cathetersmarket covered in this report is segmented –

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

How Are Trends Influencing The Drug Eluting Balloons Catheters Market?

To secure a stronger position within the drug-eluting balloon catheter marketplace, leading corporations are heavily concentrating resources on innovating next-generation devices incorporating cutting-edge capabilities. Illustratively, in March of 2024, Boston Scientific Corporation, a major American corporation renowned for its biomedical engineering and global medical device production, publicized that the U.S. Food and Drug Administration (FDA) had granted clearance for its AGENT Drug-Coated Balloon (DCB). This AGENT DCB represents a significant milestone as the inaugural coronary balloon coated with medication to be authorized within the United States specifically for managing in-stent restenosis (ISR), a condition involving the re-obstruction of a stented artery by accumulated plaque or fibrous tissue. The device utilizes a paclitaxel application to administer a therapeutic quantity of medication directly onto the vessel lining, effectively mitigating the likelihood of ISR returning without necessitating further stent placement or the use of radiation therapy; data from clinical investigations pointed towards a 49 percent reduction in heart attack occurrences at the targeted location alongside impressively low frequencies of undesirable patient outcomes.

Which Leading Players Are Enhancing Their Drug Eluting Balloons Catheters Market Presence Worldwide?

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Drug Eluting Balloons Catheters Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2025, By The Business Research Company

Narcotic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report

Antiparasitic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#How Much Larger Is The Drug Eluting Balloons Catheters Market Expected To Become By 2029 Compared With Its 2025 Level?#_x000D_

The sphere of drug-eluting balloon catheters has experienced swift expansion lately; projections indicate a rise from $1.43 billion in 2024 to $1.65 billion in 2025, reflecting a compounded annual growth rate totaling 15.4%. This historical upward trend is propelled by several factors, including the prevalence of respiratory ailments, the benefits these catheters offer compared to older inhaler methods, increased patient acceptance of dpis, supportive governmental programs focused on respiratory wellness, strategic alliances forged between entities, enhancements in how drugs are prepared, and the aging demographic’s growth._x000D_

_x000D_

Forecasting indicates that the drug-eluting balloon catheters sector is poised for substantial expansion in the approaching years, projected to reach a valuation of $2.62 billion by 2029, reflecting a compound annual growth rate of 12.2%. This upward trajectory throughout the forecasted timeframe stems from several key factors such as the persistent rise in respiratory ailments, the expanding segment of the elderly population, heightened levels of awareness and patient education, penetration into nascent global markets, development of personalized drug compositions, supportive regulatory frameworks, and advancements in the physical packaging and structural configuration of the devices. Significant shifts observed during this period are characterized by the integration of smart inhaler technology with connectivity features, a movement favoring inhalers activated purely by the patient’s breath, increased attention directed towards the specific requirements of pediatric and elderly users, the incorporation of biologics for therapeutic delivery, and a growing emphasis on creating inhalation device models that are more ecologically sustainable._x000D_

_x000D_

#Unlock Your Free Sample Report for Exclusive Market Data:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp_x000D_

_x000D_

#Which Drivers Are Supporting Growth Of The Drug Eluting Balloons Catheters Market?#_x000D_

The increasing incidence of both peripheral and cardiovascular ailments is anticipated to fuel the expansion of the market for drug-eluting balloon catheters in the future; these cardiovascular conditions affect the heart and vascular network, while peripheral artery disease specifically involves constricted arteries diminishing blood circulation, predominantly in the limbs, and drug-eluting balloon catheters serve as an intervention for coronary artery disease, utilizing a semi-compliant angioplasty balloon impregnated with an anti-proliferative agent designed to exert an anti-restenotic influence upon deployment within the vessel, as exemplified by data shared in May 2024 from the US government agency, the Centers for Disease Control and Prevention, indicating that heart disease was responsible for 702,880 fatalities in 2022, representing one fifth of all deaths, and furthermore, roughly 805,000 individuals in the United States suffer a heart attack annually, with 605,000 being initial occurrences and 200,000 happening to those with a prior history, consequently highlighting that the escalating rate of these vascular and cardiac diseases is the impetus behind the market growth for drug-eluting balloon catheters._x000D_

_x000D_

#What Are The Segment Types Shaping The Drug Eluting Balloons Catheters Market?#_x000D_

The drug eluting balloons cathetersmarket covered in this report is segmented – _x000D_

_x000D_

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters_x000D_

2) By Drug: Paclitaxel, Sirolimus, Other Drugs_x000D_

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials_x000D_

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories_x000D_

_x000D_

Subsegments:_x000D_

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters_x000D_

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters_x000D_

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters_x000D_

_x000D_

#How Are Trends Influencing The Drug Eluting Balloons Catheters Market?#_x000D_

To secure a stronger position within the drug-eluting balloon catheter marketplace, leading corporations are heavily concentrating resources on innovating next-generation devices incorporating cutting-edge capabilities. Illustratively, in March of 2024, Boston Scientific Corporation, a major American corporation renowned for its biomedical engineering and global medical device production, publicized that the U.S. Food and Drug Administration (FDA) had granted clearance for its AGENT Drug-Coated Balloon (DCB). This AGENT DCB represents a significant milestone as the inaugural coronary balloon coated with medication to be authorized within the United States specifically for managing in-stent restenosis (ISR), a condition involving the re-obstruction of a stented artery by accumulated plaque or fibrous tissue. The device utilizes a paclitaxel application to administer a therapeutic quantity of medication directly onto the vessel lining, effectively mitigating the likelihood of ISR returning without necessitating further stent placement or the use of radiation therapy; data from clinical investigations pointed towards a 49 percent reduction in heart attack occurrences at the targeted location alongside impressively low frequencies of undesirable patient outcomes._x000D_

_x000D_

#Which Leading Players Are Enhancing Their Drug Eluting Balloons Catheters Market Presence Worldwide?#_x000D_

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB_x000D_

_x000D_

#Download The Full Report For Exclusive Market Findings:#_x000D_

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report_x000D_

_x000D_

#Which Region Shows The Highest Potential For Future Expansion In The Drug Eluting Balloons Catheters Market?#_x000D_

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request A Customized Version Of The Drug Eluting Balloons Catheters Market Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2025, By The Business Research Company#_x000D_

_x000D_

Narcotic Drugs Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report_x000D_

_x000D_

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report_x000D_

_x000D_

Antiparasitic Drugs Global Market Report 2025_x000D_

https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Fast Is The Drug Eluting Balloons Catheters Market Expected to Grow Between 2025 And 2029?#_x000D_

In recent years, the market size of drug eluting balloons catheters has experienced significant growth. It is projected to rise from $1.43 billion in 2024 to $1.65 billion in 2025, representing a compound annual growth rate (CAGR) of 15.4%. The growth during the historical timeframe has been driven by factors such as escalating instances of respiratory disorders, the benefits of these catheters over conventional inhalers, patient inclination towards dpis, governmental efforts to improve respiratory health, strategic alliances and partnerships, drug formulation advancements, and a surging elderly population._x000D_

_x000D_

The market for drug eluting balloons catheters is projected to experience considerable expansion in the upcoming years, swelling to $2.62 billion in 2029, with a compound annual growth rate (CAGR) of 12.2%. The escalation in the projected period can be accounted for by consistent progression in respiratory disorders, a booming aging population, surging awareness and education, market proliferation in budding economies, bespoke medicine formulations, regulatory support and adherence, and advancements in packaging and design. Key trends over this period encompass the rise in use of smart inhalers and connecting technologies, a shift towards breath-actuated inhalers, concentration on the needs of pediatric and elderly patients, biologics delivery, and eco-friendly inhaler designs._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Drug Eluting Balloons Catheters Market?#_x000D_

The drug-eluting balloon catheter market is predicted to see an increase in growth, driven by the rising incidence of peripheral and cardiovascular diseases. Cardiovascular diseases (CVDs) relate to a series of conditions affecting the heart and blood vessels, whereas peripheral artery disease (PAD) commonly refers to a situation where narrowed arteries limit the blood flow to the limbs primarily. Drug-eluting balloon catheters offer a treatment option for coronary artery disease (CAD), using a semi-compliant angioplasty balloon covered with an anti-proliferative drug that can prevent re-narrowing of the vessel upon entry. For example, the Centers for Disease Control and Prevention, a US-based government organization, reported in May 2024 that heart disease caused the deaths of 702,880 individuals in 2022, corresponding to 1 out of every 5 deaths. Around 805,000 people suffer a heart attack annually in the United States, with 605,000 experiencing their first episode and 200,000 having had previous heart attacks. This increasing prevalence of peripheral and cardiovascular diseases is propelling the expansion of the drug-eluting balloon catheter market._x000D_

_x000D_

#How Is the Drug Eluting Balloons Catheters Market Segmented?#_x000D_

The drug eluting balloons cathetersmarket covered in this report is segmented – _x000D_

_x000D_

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters_x000D_

2) By Drug: Paclitaxel, Sirolimus, Other Drugs_x000D_

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials_x000D_

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories_x000D_

_x000D_

Subsegments:_x000D_

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters_x000D_

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters_x000D_

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Drug Eluting Balloons Catheters Market Growth?#_x000D_

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Drug Eluting Balloons Catheters Market?#_x000D_

Key players in the drug-eluting balloon catheter sector are intensifying their focus on the creation of cutting-edge, next-gen products with superior technology to gain a leading position. An illustration of this is the March 2024 announcement by Boston Scientific Corporation, an American biomedical/biotechnology engineering company and global medical device manufacturer. They reported securing approval from the U.S. Food and Drug Administration (FDA) for their AGENT Drug-Coated Balloon (DCB). AGENT DCB, the pioneer drug-coated coronary balloon to be available in the U.S, is designed to treat in-stent restenosis (ISR), a condition characterized by plaque or scar tissue obstructing a stented vessel. Unique features of AGENT DCB include its paclitaxel coating which administers a therapeutic dose to the vessel wall, thereby reducing the recurrence of ISR without needing any extra stents or radiation. Trials in clinical settings indicated a 49% reduction in heart attack risk at the target location and manifested minimal rates of adverse incidents._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report_x000D_

_x000D_

#How Is the Drug Eluting Balloons Catheters Market Defined and What Are Its Core Parameters?#_x000D_

A drug-eluting balloon catheter is a medical device used to treat coronary artery disease by percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon coated with an anti-proliferative drug that is released into the vessel wall during inflation, which helps to prevent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Drug Eluting Balloons Catheters Market Size Changed, over the years?

The market size for drug eluting balloons catheters has experienced swift growth recently. It is projected to inflate from $1.43 billion in 2024 to $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 16.0%. Factors contributing to the past expansion include the rise in respiratory disorders, benefits compared to conventional inhalers, patient inclination towards dpis, government interventions for respiratory health, strategic collaborations and partnerships, advancements in drug composition, and a growing elderly population.

How Much Will the Drug Eluting Balloons Catheters Market Be Worth in 2029?

In the coming years, the market size for drug eluting balloons catheters is predicted to experience a swift expansion, reaching $2.61 billion in 2029 with an annual compound growth rate of 12.0%. This anticipated growth in the forecast period can be credited to ongoing increases in respiratory disorders, the broadening geriatric population, heightened awareness and education, emerging economies expanding their market, tailored drug formulations, regulatory backing and adherence, as well as packaging and design innovations. The forecast period also expects to see significant trends like smart inhalers with connectivity, a shift towards breath-based inhalers, focus on the needs of pediatric and geriatric patients, biologics delivery, and eco-friendly inhaler designs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which is the Largest Company in the Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

What Are the Main Market Drivers in the Drug Eluting Balloons Catheters Industry?

The drug-eluting balloon catheter market’s growth is anticipated to be fueled by the escalating prevalence of peripheral and cardiovascular diseases. Peripheral artery disease (PAD) primarily involves the narrowing of arteries that diminishes blood flow, particularly to the arms or legs, whereas cardiovascular diseases (CVDs) affect the heart and blood vessels. Drug-eluting balloon catheters, which utilize a semi-compliant angioplasty balloon enriched with an anti-proliferative agent, serve as a therapeutic strategy in battling coronary artery disease (CAD). They can act to prevent the recurrence of vascular narrowing once inside the vessel. For instance, in 2022, heart disease was responsible for approximately one-fifth of all deaths, claiming 702,880 lives, as reported by the Centers for Disease Control and Prevention in May 2024. In the United States, each year sees around 805,000 heart attacks, with 605,000 being first-time occurrences and 200,000 involving individuals with a previous history. As such, the drug-eluting balloon catheter market is boosted by the rising occurrences of peripheral and cardiovascular diseases.

Drug Eluting Balloons Catheters Market Driver: Surging demand For Minimally Invasive Techniques Boosts Drug-Eluting Balloon Catheter Market Expansion

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

How Is the Drug Eluting Balloons Catheters Market Segments Structured?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

What Strategic Trends Are Transforming the Drug Eluting Balloons Catheters Market?

Leading businesses in the drug-eluting balloon catheter market are putting more emphasis on crafting the latest generation of products utilizing cutting-edge technologies. They aim to acquire a competitive advantage in the market. For instance, in March 2024, Boston Scientific Corporation, a multinational manufacturer of medical appliances from the US and also a biomedical/biotechnology engineering enterprise, announced that it had earned approval from the U.S. Food and Drug Administration for its AGENT Drug-Coated Balloon (DCB). This innovative AGENT DCB is the inaugural drug-coated coronary balloon accessible in the U.S. for in-stent restenosis (ISR) treatment, a condition where a stented vessel is obstructed by plaque or scar tissue. It possesses a paclitaxel coating, which provides a therapeuticdosage to the vessel wall, thereby diminishing ISR recurrence without the need for extra stents or radiation. Trials in a clinical setting have demonstrated a 49% reduction in heart attack risk at the targeted site, with minimal reported adverse incidents.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Global Regions Offer the Highest Growth in the Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429

This Report Delivers Insight On:

1. How big is the drug eluting balloons catheters market, and how is it changing globally?

2. Who are the major companies in the drug eluting balloons catheters market, and how are they performing?

3. What are the key opportunities and risks in the drug eluting balloons catheters market right now?

4. Which products or customer segments are growing the most in the drug eluting balloons catheters market?

5. What factors are helping or slowing down the growth of the drug eluting balloons catheters market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Drug Eluting Balloons Catheters Market Size Changed, over the years?

The market size for drug eluting balloons catheters has experienced swift growth recently. It is projected to inflate from $1.43 billion in 2024 to $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 16.0%. Factors contributing to the past expansion include the rise in respiratory disorders, benefits compared to conventional inhalers, patient inclination towards dpis, government interventions for respiratory health, strategic collaborations and partnerships, advancements in drug composition, and a growing elderly population.

How Much Will the Drug Eluting Balloons Catheters Market Be Worth in 2029?

In the coming years, the market size for drug eluting balloons catheters is predicted to experience a swift expansion, reaching $2.61 billion in 2029 with an annual compound growth rate of 12.0%. This anticipated growth in the forecast period can be credited to ongoing increases in respiratory disorders, the broadening geriatric population, heightened awareness and education, emerging economies expanding their market, tailored drug formulations, regulatory backing and adherence, as well as packaging and design innovations. The forecast period also expects to see significant trends like smart inhalers with connectivity, a shift towards breath-based inhalers, focus on the needs of pediatric and geriatric patients, biologics delivery, and eco-friendly inhaler designs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

Which is the Largest Company in the Drug Eluting Balloons Catheters Market?

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

What Are the Main Market Drivers in the Drug Eluting Balloons Catheters Industry?

The drug-eluting balloon catheter market’s growth is anticipated to be fueled by the escalating prevalence of peripheral and cardiovascular diseases. Peripheral artery disease (PAD) primarily involves the narrowing of arteries that diminishes blood flow, particularly to the arms or legs, whereas cardiovascular diseases (CVDs) affect the heart and blood vessels. Drug-eluting balloon catheters, which utilize a semi-compliant angioplasty balloon enriched with an anti-proliferative agent, serve as a therapeutic strategy in battling coronary artery disease (CAD). They can act to prevent the recurrence of vascular narrowing once inside the vessel. For instance, in 2022, heart disease was responsible for approximately one-fifth of all deaths, claiming 702,880 lives, as reported by the Centers for Disease Control and Prevention in May 2024. In the United States, each year sees around 805,000 heart attacks, with 605,000 being first-time occurrences and 200,000 involving individuals with a previous history. As such, the drug-eluting balloon catheter market is boosted by the rising occurrences of peripheral and cardiovascular diseases.

Drug Eluting Balloons Catheters Market Driver: Surging demand For Minimally Invasive Techniques Boosts Drug-Eluting Balloon Catheter Market Expansion

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

How Is the Drug Eluting Balloons Catheters Market Segments Structured?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

What Strategic Trends Are Transforming the Drug Eluting Balloons Catheters Market?

Leading businesses in the drug-eluting balloon catheter market are putting more emphasis on crafting the latest generation of products utilizing cutting-edge technologies. They aim to acquire a competitive advantage in the market. For instance, in March 2024, Boston Scientific Corporation, a multinational manufacturer of medical appliances from the US and also a biomedical/biotechnology engineering enterprise, announced that it had earned approval from the U.S. Food and Drug Administration for its AGENT Drug-Coated Balloon (DCB). This innovative AGENT DCB is the inaugural drug-coated coronary balloon accessible in the U.S. for in-stent restenosis (ISR) treatment, a condition where a stented vessel is obstructed by plaque or scar tissue. It possesses a paclitaxel coating, which provides a therapeuticdosage to the vessel wall, thereby diminishing ISR recurrence without the need for extra stents or radiation. Trials in a clinical setting have demonstrated a 49% reduction in heart attack risk at the targeted site, with minimal reported adverse incidents.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Global Regions Offer the Highest Growth in the Drug Eluting Balloons Catheters Market?

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429

This Report Delivers Insight On:

1. How big is the drug eluting balloons catheters market, and how is it changing globally?

2. Who are the major companies in the drug eluting balloons catheters market, and how are they performing?

3. What are the key opportunities and risks in the drug eluting balloons catheters market right now?

4. Which products or customer segments are growing the most in the drug eluting balloons catheters market?

5. What factors are helping or slowing down the growth of the drug eluting balloons catheters market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Drug Eluting Balloons Catheters Market?

The escalating incidences of peripheral and cardiovascular diseases are predicted to fuel the growth of the drug-eluting balloon catheter market in the near future. A host of conditions affecting the heart and circulatory system are encompassed by cardiovascular diseases (CVDs) while peripheral artery disease (PAD) pertains specifically to a state in which blood flow, primarily to the arms or legs, is reduced due to constricted arteries. Drug-eluting balloon catheters, which are a treatment alternative for coronary artery disease (CAD), consist of anti-proliferative substance-coated semi-compliant angioplasty balloons that can create an anti-restenotic effect when introduced into the vessel. To illustrate, as per the Centers for Disease Control and Prevention, a US-based governmental agency, heart disease was responsible for the death of 702,880 individuals in 2022, equating to one in every five deaths. In the United States, almost 805,000 people have a heart attack each year, with 605,000 experiencing their first heart attack and 200,000 having had prior heart attacks. Consequently, the escalating occurrence of peripheral and cardiovascular diseases propels the drug-eluting balloon catheter market.

Drug Eluting Balloons Catheters Market Driver: Growth in Drug-Eluting Balloon Catheter Market Spurred by Demand for Minimally Invasive Procedures

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp

What is the Predicted Annual Growth Rate of theDrug Eluting Balloons Catheters Market Impact Industry Trends by 2034?

The market size for drug eluting balloons catheters has experienced rapid expansion in recent times. The market value is projected to increase from $1.43 billion in 2024 to $1.66 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.0%. The historical growth can be linked to factors like a surge in respiratory disorders, benefits of these devices over traditional inhalers, patient inclination towards dpis, governmental initiatives to improve respiratory health, strategic collaborations and partnerships, advancements in drug formulations, and an increasingly aging population.

In the coming years, the market size of drug eluting balloons catheters is anticipated to undergo swift expansion. It is projected to attain a value of $2.61 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 12.0%. This predicted growth in the forecast period can be ascribed to factors such as increasing occurrence of respiratory diseases, swelling elderly population, heightened awareness and education, market broadening in budding economies, specialized drug mixtures, compliance and support from regulations, as well as innovation in packaging and design. The key trends expected during this forecast period encompass smart inhalers and connectivity, a transition to breath-actuated inhalers, emphasis on pediatric and geriatric patient requirements, delivery of biologics, and eco-friendly inhaler designs.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429

What Are the Most Significant Market Trends Transforming theDrug Eluting Balloons Catheters Market?

Prominent companies in the drug-eluting balloon catheter market are devoting their resources towards development of cutting-edge, next-generation products, aiming to secure their lead in the market. For example, in March 2024, Boston Scientific Corporation, an American multinational that specializes in biotechnology and biomedical engineering and manufactures medical devices, announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) for their AGENT Drug-Coated Balloon (DCB). The AGENT DCB is the first coronary drug-coated balloon to be made available in the U.S for the treatment of in-stent restenosis (ISR), a condition where a stented vessel is obstructed by plaque or scar tissue. This balloon features a coating of paclitaxel which delivers a therapeutic dosage to the vessel wall, thereby lowering the chances of ISR recurrence without the necessity for additional stents or radiation. Clinical studies have reported a 49% reduction in the risk of heart attack at the target site and have reported minimal rates of negative side effects.

What Are the Top Market Players Propelling the Growth of theDrug Eluting Balloons Catheters Industry?

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/drug-eluting-balloons-catheters-global-market-report

Which Primary Segments of the Drug Eluting Balloons Catheters Market Are Driving Growth and Industry Transformations?

The drug eluting balloons catheters market covered in this report is segmented –

1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters

2) By Drug: Paclitaxel, Sirolimus, Other Drugs

3) By Raw Material: Nylon, Polyurethane, Other Raw Materials

4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories

Subsegments:

1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters

2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters

3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Drug Eluting Balloons Catheters Market?# Market?

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Drug Eluting Balloons Catheters Market 2025, By The Business Research Company:

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-mds-drugs-global-market-report

Narcotic Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: